Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: Crossing the blood-brain barrier divide

Expert Opinion on Drug Delivery

Volumn 10, Issue 7, 2013, Pages 907-926

  Chacko, Ann Marie ^a,b   Li, Chunsheng ^c   Pryma, Daniel A ^a   Brem, Steven ^d   Coukos, George ^c   Muzykantov, Vladimir ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Blood brain barrier; Blood brain tumor barrier; Brain cancer; CNS; Imaging; Immunotargeting

Indexed keywords

3F 8; 81C 6; ANTIBODY; ANTINEOPLASTIC AGENT; BASILIXIMAB; BEVACIZUMAB; CEDIRANIB; DACLIZUMAB; DASATINIB; ERLOTINIB; IMC 3G 3; IRINOTECAN; LOMUSTINE; MAB 425; ME 1 14; MGA 271; MOC 31; MONOCLONAL ANTIBODY; NEURADIAB; NIMOTUZUMAB; OLARATUMAB; PANITUMUMAB; R 04929097; RAMUCIRUMAB; SORAFENIB; TEMOZOLOMIDE; TNT 1B; TPI 287; TRC 105; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BRAIN; BRAIN CANCER; BRAIN TUMOR; BREAST CANCER; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; DISULFIDE BOND; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; LEPTOMENINGEAL CANCER; LUNG CANCER; LYMPHOMA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARENCHYMA; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; RADIOSURGERY; REVIEW; RISK; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; NEUROIMAGING; PHARMACEUTICAL PREPARATIONS;

EID: 84879399902     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.808184     Document Type: Review

References (148)

1. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2008. Central Brain Tumor Registry of the United States, Hinsdale, IL; 2012
2. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14:v1-v49
3. Gurney JG, Smith MA, Bunin GR. Chapter III: CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program; Bethesda, MD: 1999
4. Bernstein M, Berger MS. Neurooncology: the essentials. 2nd edition. Thieme Medical Publishers, Inc; New York: 2008
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
6. Pardridge WM. Drug targeting, drug discovery, and brain drug development. Cambridge University Press; Cambridge: 2001
7. Bluml S, McKeever K, Ettinger R, et al. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013;15(Suppl 1):S4
8. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-34
9. Pardridge WM. Vector-mediated peptide drug-delivery to the brain. Adv Drug Deliv Rev 1995;15:109-46
10. Frank RN, Dutta S, Mancini MA. Pericyte coverage is greater in the retinal than in the cerebral capillaries of the rat. Invest Ophthalmol Vis Sci 1987;28:1086-91
11. Johanson CE. Permeability and vascularity of the developing brain: cerebellum vs cerebral cortex. Brain Res 1980;190:3-16
12. Kapadia SE, de Lanerolle NC. Immunohistochemical and electron microscopic demonstration of vascular innervation in the mammalian brainstem. Brain Res 1984;292:33-9
13. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38:323-37
14. Miller FN, Sims DE. Contractile elements in the regulation of macromolecular permeability. Fed Proc 1986;45:84-8
15. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47-62
16. Saunders NR, Ek CJ, Habgood MD, et al. Barriers in the brain: a renaissance? Trends Neurosci 2008;31:279-86
17. Saunders NR, Knott GW, Dziegielewska KM. Barriers in the immature brain. Cell Mol Neurobiol 2000;20:29-40
18. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, II. Immature brain. Clin Exp Pharmacol Physiol 1999;26:85-91
19. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol 1999;26:11-19
20. Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol 2000;20:149-63
21. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53
22. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90-105.51
23. Schlageter KE, Molnar P, Lapin GD, et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28
24. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000;2:45-59
25. Agarwal S, Sane R, Oberoi R, et al. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011;13:e17
26. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000;100:323-31
27. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol 1989;78:561-71
28. Ningaraj NS. Drug delivery to brain tumours: challenges and progress. Expert Opin Drug Deliv 2006;3:499-509
29. Sarin H, Kanevsky AS, Wu H, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008;6:80
30. Squire JM, Chew M, Nneji G, et al. Quasi-periodic substructure in the microvessel endothelial glycocalyx: a possible explanation for molecular filtering? J Struct Biol 2001;136:239-55
31. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84
32. Boucher Y, Salehi H, Witwer B, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997;75:829-36
33. Navalitloha Y, Schwartz ES, Groothuis EN, et al. Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro Oncol 2006;8:227-33
34. Gumerlock MK, Neuwelt EA. Therapeutic opening of the blood-brain barrier in man. In: Bradbury MWB, editor. Physiology and pharmacology of the blood-brain barrier. Spinger, Berlin; 1992. p. 525-42
35. Vavra M, Ali MJ, Kang EW, et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 2004;6:104-12
36. Netti PA, Baxter LT, Boucher Y, et al. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995;55:5451-8
37. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78
38. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008;6:515-22
39. Brem S, Wong E. Angiogenesis and brain tumors: molecular targets and molecular scalpels. In: Winn HR, editor. Youmans neurological surgery. 6th edition. Elsevier; Philadelphia: 2011. p. 1151-17.e271-277
40. Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005;3:38
41. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96
42. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-18
43. Perk LR, Visser GW, Vosjan MJ, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898-906
44. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-31
45. Sivasankaran B, Degen M, Ghaffari A, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 2009;69:458-65
46. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-8
47. Reardon DA, Zalutsky MR, Akabani G, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008;10:182-9
48. Kuan CT, Wakiya K, Herndon JE II, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010;10:468
49. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012;17:954-63
50. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010;2:129-36
51. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009;46:167-89
52. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117
53. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012;526:194-205
54. Madhumathi J Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012;15:300-9
55. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
56. Poduslo JF, Curran GL. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J Neurochem 1996;67:734-41
57. Poduslo JF, Curran GL. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem 1996;66:1599-609
58. Triguero D, Buciak JB, Yang J, et al. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989;86:4761-5
59. Vorbrodt AW, Lossinsky AS, Dobrogowska DH, et al. Distribution of anionic sites and glycoconjugates on the endothelial surfaces of the developing blood-brain barrier. Brain Res 1986;394:69-79
60. Danielyan K, Ding BS, Gottstein C, et al. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther 2007;321:947-52
61. Ramakrishnan M, Wengenack TM, Kandimalla KK, et al. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res 2008;25:1861-72
62. Foley TL, Burkart MD. Site-specific protein modification: advances and applications. Curr Opin Chem Biol 2007;11:12-19
63. Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 2008;19:1327-38
64. Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006;83:154-60
65. Uotani S, Bjorbaek C, Tornoe J, et al. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999;48:279-86
66. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 1990;54:1882-8
67. Tuma P, Hubbard AL. Transcytosis: crossing cellular barriers. Physiol Rev 2003;83:871-932
68. Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005;313:1075-81
69. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res 1999;59:6159-63
70. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011;3:84ra44
71. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001;114:168-72
72. Rapoport SI. Effect of concentrated solutions on blood-brain barrier. Am J Physiol 1970;219:270-4
73. Neuwelt EA, Specht HD, Barnett PA, et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 1987;20:885-95
74. Blanchette M, Pellerin M, Tremblay L, et al. Real-time monitoring of gadolinium diethylenetriamine penta-Acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal wistar rats. Neurosurgery 2009;65:344-50
75. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008;10:166-77
76. Abbott NJ, Revest PA. Control of brain endothelial permeability. Cerebrovasc Brain Metab Rev 1991;3:39-72
77. Rapoport SI, Robinson PJ. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann N Y Acad Sci 1986;481:250-67
78. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37:17-27.discussion 27-8
79. Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005;103:2606-15
80. Fortin D, Gendron C, Boudrias M, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007;109:751-60
81. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 2011;114:624-32
82. Shin BJ, Burkhardt JK, Riina HA, et al. Superselective intra-Arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 2012;23:323-9.ix-x
83. Burkhardt JK, Riina H, Shin BJ, et al. Intra-Arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 2012;77:130-4
84. Miller G. Drug targeting. Breaking down barriers. Science 2002;297:1116-18
85. Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004;30:415-23
86. Brown RC, Egleton RD, Davis TP. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res 2004;1014:221-7
87. Fortin D, Salame JA, Desjardins A, et al. Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. AJNR Am J Neuroradiol 2004;25:830-4
88. Remsen LG, Pagel MA, McCormick CI, et al. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Anesth Analg 1999;88:559-67
89. Hochberg FH, Pruitt AA, Beck DO, et al. The rationale and methodology for intra-Arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 1985;63:876-80
90. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-47
91. Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther 1994;271:229-37
92. Sanovich E, Bartus RT, Friden PM, et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995;705:125-35
93. Emerich DF, Snodgrass P, Dean R, et al. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 1999;80:964-70
94. Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006;58:343-7
95. Prados MD, Schold SJS, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol 2003;5:96-103
96. Ningaraj NS, Rao M, Hashizume K, et al. Regulation of blood-brain tumor barrier permeability by calcium-Activated potassium channels. J Pharmacol Exp Ther 2002;301:838-51
97. Baba T, Chio CC, Black KL. The effect of 5-lipoxygenase inhibition on blood-brain barrier permeability in experimental brain tumors. J Neurosurg 1992;77:403-6
98. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg 1992;77:407-10
99. Walker WL, Cook J. Drug delivery to brain tumors. Bull Math Biol 1996;58:1047-74
100. Salkoff L, Butler A, Ferreira G, et al. High-conductance potassium channels of the SLO family. Nat Rev Neurosci 2006;7:921-31
101. Pedersen SF, Stock C. Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res 2013;73:1658-61
102. Ningaraj NS, Sankpal UT, Khaitan D, et al. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Cancer Biol Ther 2009;8:1924-33
103. Ransom CB, Sontheimer H. BK channels in human glioma cells. J Neurophysiol 2001;85:790-803
104. Sontheimer H, Black JA, Waxman SG. Voltage-gated Na+ channels in glia: properties and possible functions. Trends Neurosci 1996;19:325-31
105. Black KL, Yin D, Konda BM, et al. Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models. Brain Res 2008;1227:198-206
106. Hynynen K, McDannold N, Vykhodtseva N, et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001;220:640-6
107. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 2008;60:1209-17
108. Sheikov N, McDannold N, Sharma S, et al. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 2008;34:1093-104
109. Shang X, Wang P, Liu Y, et al. Mechanism of low-frequency ultrasound in opening blood-tumor barrier by tight junction. J Mol Neurosci 2011;43:364-9
110. Sheikov N, McDannold N, Jolesz F, et al. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med Biol 2006;32:1399-409
111. Yang FY, Lin GL, Horng SC, et al. Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood-tumor barrier in a glioma-bearing rat model. IEEE Trans Ultrason Ferroelectr Freq Control 2011;58:964-70
112. Yang FY, Teng MC, Lu M, et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int J Nanomedicine 2012;7:965-74
113. Hynynen K, McDannold N, Sheikov NA, et al. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005;24:12-20
114. McDannold N, Vykhodtseva N, Raymond S, et al. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol 2005;31:1527-37
115. Hynynen K, McDannold N, Vykhodtseva N, et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 2006;105:445-54
116. Baseri B, Choi JJ, Tung YS, et al. Multi-modality safety assessment of blood-brain barrier opening using focused ultrasound and definity microbubbles: a short-term study. Ultrasound Med Biol 2010;36:1445-59
117. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255:415-25
118. Kinoshita M, McDannold N, Jolesz FA, et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 2006;103:11719-23
119. Park EJ, Zhang YZ, Vykhodtseva N, et al. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release 2012;163:277-84
120. Qin DX, Zheng R, Tang J, et al. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 1990;19:1507-10
121. Lemasson B, Serduc R, Maisin C, et al. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology 2010;257:342-52
122. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005;23:4127-36
123. Patel RR, Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 2007;13:1675-83
124. Li YQ, Chen P, Haimovitz-Friedman A, et al. Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res 2003;63:5950-6
125. Yuan H, Gaber MW, Boyd K, et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006;66:860-6
126. van Vulpen M, Kal HB, Taphoorn MJ, et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 2002;9:683-8
127. Diserbo M, Agin A, Lamproglou I, et al. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can J Physiol Pharmacol 2002;80:670-8
128. Reinhold HS, Calvo W, Hopewell JW, et al. Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys 1990;18:37-42
129. Mima T, Toyonaga S, Mori K, et al. Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol Res 1999;21:209-15
130. Baumann BC, Benci JL, Santoiemma PP, et al. An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform. Transl Oncol 2012;5:230-7
131. Baumann BC, Kao GD, Mahmud A, et al. Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy. Oncotarget 2012;4(1):64-79
132. Jain R, Ellika SK, Scarpace L, et al. Quantitative estimation of permeability surface-Area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008;29:694-700
133. Saha GB, MacIntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. Semin Nucl Med 1994;24:324-49
134. Webb S, Ott RJ, Cherry SR. Quantitation of blood-brain barrier permeability by positron emission tomography. Phys Med Biol 1989;34:1767-71
135. Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172-87
136. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51
137. Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. Radiology 1990;174:411-15
138. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988;38:1371-4
139. Ott RJ, Brada M, Flower MA, et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991;27:1356-61
140. Dhawan V, Jarden JO, Moeller JR, et al. Positron emission tomographic measurement of blood-to-brain and blood-to-tumour transport of 82Rb. II: Clinical data and validation of technique. Phys Med Biol 1989;34:1785-94
141. Zunkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85:1056-65
142. Kraemer DF, Fortin D, Doolittle ND, et al. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-Acquired immunodeficiency syndrome) and survival. Neurosurgery 2001;48:1033-40.discussion 40-1
143. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008;29:193-207
144. Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10-29
145. Saleem A, Brown GD, Brady F, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003;63:2409-15
146. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006;12:5288-97
147. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52
148. Chen L, Zhang Y, Yang J, et al. Vertebrate animal models of glioma: Understanding the mechanisms and developing new therapies. Biochimica et Biophysica Acta 2013;1836(1):158-65